Financials data is unavailable for this security.
View more
Year on year Kidswell Bio Corp 's revenues fell -12.43% from 2.78bn to 2.43bn. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from a loss of 657.43m to a larger loss of 1.42bn.
Gross margin | 42.46% |
---|---|
Net profit margin | -39.33% |
Operating margin | -37.32% |
Return on assets | -29.48% |
---|---|
Return on equity | -152.15% |
Return on investment | -47.94% |
More ▼
Cash flow in JPYView more
In 2024, Kidswell Bio Corp increased its cash reserves by 109.10%, or 1.16bn. Cash Flow from Financing totalled 1.62bn or 66.55% of revenues. In addition the company used 453.63m for operations while cash used for investing totalled .
Cash flow per share | -30.34 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 18.12 |
---|---|
Tangible book value per share | 18.08 |
More ▼
Balance sheet in JPYView more
Current ratio | 2.04 |
---|---|
Quick ratio | 1.45 |
Total debt/total equity | 3.36 |
---|---|
Total debt/total capital | 0.7709 |
More ▼